Who can use Canakinumab(ILARIS)?

Periodic Fever Syndromes

Canakinumab (ILARIS) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory periodic fever syndromes:

(1) Cryopyrin-Associated Periodic Syndromes (CAPS)

Canakinumab is indicated for the treatment of cryopyrin-associated periodic syndromes in adult and pediatric patients aged 4 years and older, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).

(2) Tumor Necrosis Factor Receptor (TNF)-Associated Periodic Syndrome (TRAPS)

Canakinumab is indicated for the treatment of tumor necrosis factor receptor-associated periodic syndrome in adult and pediatric patients.

(3) Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)

Canakinumab is indicated for the treatment of hyperimmunoglobulin D syndrome/mevalonate kinase deficiency in adult and pediatric patients.

(4) Familial Mediterranean Fever (FMF)

Canakinumab is indicated for the treatment of familial Mediterranean fever in adult and pediatric patients.

Still's Disease

Canakinumab is indicated for the treatment of active Still's disease in patients aged 2 years and older, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA).

Gout Flares

Canakinumab is indicated for the symptomatic treatment of recurrent gout flares in adult patients who are intolerant of, have a contraindication to, or have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine, as well as in patients who are not suitable for repeated treatment with corticosteroids.